To explore the predictive and diagnostic role of biomarkers in patients with neurological diseases.

With the rise and continuous development of omics technology and bioinformatics technology, some scholars have applied proteomics technology and metabolomics technology to study the brain tissue, plasma and CSF of patients with nervous system diseases, so as to screen out potential biomarkers, with a view to providing new research ideas for pathogenesis and early diagnosis of neurological diseases. At present, the research on some novel biomarkers is still in its infancy, and many key problems remain to be solved. It is necessary to further determine the expression level of biomarkers in normal human body and the characteristics of biomarkers in patients with neurological diseases.

Inclusion Criteria:

1. Patients with neurological diseases;
2. Subjects or legal agents agree to participate in the study and sign the informed consent.

Exclusion Criteria:

1. Participating in other clinical investigators;
2. Unwilling to be followed up or poor treatment compliance;
3. Other conditions considered unsuitable for inclusion by the researchers.

Patients with neurological diseases admitted to hospital/emergency department.